LIMITED TICKETS REMAINING

July 29-31, 2025 | Boston, MA

www.rnaediting-summit.com

WELCOME | EXPERT SPEAKERS | AGENDA | PARTNER WITH US | REGISTER YOUR PLACE

6th Annual

RNA Editing Summit

Accelerating the Next Wave of RNA Editing Drugs to Patients

Building Novel RNA Editors with Optimized Efficiency, Target Selection, & Extra-Hepatic Delivery to Progress Safe & Efficacious Therapies into the Clinic for Rare & Common Diseases

Expert Speakers Include:

Ram Aiyar
Chief Executive Officer
Korro Bio

Tehmina Masud
Vice President & Head of Systems & Target Biology
Deep Genomics

TJ Cradick
Chief Technology Officer
HuidaGene Therapeutics

Paul Bolno
Chief Executive Officer
Wave Life Sciences

Robert Deans
Chief Technology Officer
Rett Syndrome Research Trust

Sriram Sathy
Chief Scientific Officer
AIRNA

Proud to Partner With:

SynOligo BIOTECHNOLOGIES | CHEMGENES | WAVE LIFE SCIENCES

+1 617 455 4188 | info@hansonwade.com | World RNA Events Series

www.rnaediting-summit.com

hansonwade

Welcome to the 6th RNA Editing Summit

RNA Editing Summit

July, 29-31, 2025 | Boston, MA

With **Wave Life Sciences** and **Korro Bio** advancing drugs into the clinic, new biotech and pharma partnerships developing, and **ProQR** and **AIRNA**'s recent investment funding, the floodgates have opened for the RNA editing industry, creating new opportunities to expand therapeutic pipelines and forge a path to the clinic.

The **6th RNA Editing Summit** returns to Boston as the world's leading industry-dedicated forum focused on advancing the discovery and development of RNA modifying therapies, showcasing novel, innovative editing technologies, translational and functional biology and groundbreaking clinical data.

Uniting RNA editing leaders from the likes of **Korro Bio**, **Shape Therapeutics**, **Deep Genomics**, **HuidaGene Therapeutics** and more, **this three day deep-dive meeting will focus on:**

- Presenting new clinical insights from industry leaders to guide your strategies toward clinical success, helping RNA editors reach patients more quickly
- Showcasing innovative RNA editing technologies, including ADAR, exon splicing, and CRISPR-based editors, to target previously undruggable diseases
- Achieving extra-hepatic delivery with novel carrier formulations for transporting RNA editor payloads of any size, broadening treatment indications
- Exploring functional assays and machine learning for target discovery and design, providing technical insights to accelerate your research

Connect with 60+ experts in **Platform Biology**, **Chemistry** and **R&D** for an unrivalled learning and networking opportunity designed to accelerate preclinical RNA editing candidates towards clinical development, as the next wave of therapies moves ever closer to patients in need.

What's New for 2025?

New Speaking Companies: **Deep Genomics, HuidaGene Therapeutics** & **Rett Syndrome Research Trust**

CEOs' Fireside Chat with:

WAVE LIFE SCIENCES

AIRNA

KORRO BIO

Key Benefits of Attending

Maximize modification magnitude by improving editing efficiency, with lessons on designing robust, targeted guide RNA to improve extra-hepatic delivery, increase bioavailability and minimize off-target effects with **Korro Bio** and **ProQR Therapeutics**

Unleash the potential of RNA editing through a deeper understanding of RNA and ADAR biology, and gain insights into novel editing machinery including multi-kilobase, edits and cas-based systems, with **Amber Bio** and **UC Davis**



Achieve the full therapeutic impact of RNA modification by differentiating targets and exploring novel technologies to edit multiple mutations with the scope to expand into common disease, with **Deep Genomics**, **Jorna Therapeutics** and **Radar Therapeutics**



Navigate the path to the clinic by overcoming the limitations of preclinical models, unravelling complex regulatory guidelines, and hearing first-hand success stories from the pioneers of RNA editing, with **HuidaGene Therapeutics** and **Wave Life Sciences**

Explore the investment and partnering landscape to attract funding and ensure success in driving investigational RNA editors into clinically and commercially viable therapies, with **Jefferies**, **Chardan** and **Cantor Fitzgerald**

+1 617 455 4188 info@hansonwade.com World RNA Events Series
www.rnaediting-summit.com
hansonwade

Your Expert Speakers

RNA Editing Summit
July, 29-31, 2025 | Boston, MA

RNA Editing Experts

Jacob Borrajo
Founder & Chief Executive Officer
Amber Bio

Sriram Sathy
Chief Scientific Officer
AIRNA

Kris Elverum
Chief Executive Officer
AIRNA

Jeff Wintersinger
Senior Computational Biologist
Deep Genomics

Tehmina Masud
Vice President & Head of Systems & Target Biology
Deep Genomics



Jonathan Gootenberg
Assistant Professor
Harvard Medical School



Omar Abudayyeh
Assistant Professor
Harvard Medical School

TJ Cradick
Chief Technology Officer
HuidaGene Therapeutics

Alan Herbert
Founder
InsideOutBio

Vincent DiGiacomo
Director, Therapeutic Innovation
Jorna Therapeutics

Maryam Habibian
Director, Head of Medicinal Chemistry
Korro Bio

Ram Aiyar
Chief Executive Officer
Korro Bio
IN THE CLINIC

Venkat Krishnamurthy
Senior Vice President & Head of Platform, RNA Editing
Korro Bio
IN THE CLINIC

Gerard Platenburg
Chief Scientific Officer
ProQR Therapeutics

Andrew Fraley
Chief Innovation Officer
Radar Therapeutics

Robert Deans
Chief Technology Officer
Rett Syndrome Research Trust

Yang Gao
Assistant Professor
Rice University

Brian Booth
Director, Computational Biology RNAfix
Shape Therapeutics

Chad Weldy
Instructor, Cardiovascular Medicine
Stanford University

Peter Nell
Chief Executive Officer
Stealth Biotech

Peter Beal
Professor
UC Davis

Artem Nemudryi
Assistant Professor
University of Florida

Paul Bolno
Chief Executive Officer
Wave Life Sciences
IN THE CLINIC

Anna Dudkina
Independent RNA Editing Expert

Investment Experts

Steve Seedhouse
Biotechnology Equity Research
Cantor Fitzgerald

Keay Nakae
Director of Research
Chardan

Roger Song
Senior Equity Research Analyst
Jefferies

Pre-Conference Workshop Day
Tuesday | July 29, 2025

RNA Editing Summit
July, 29-31, 2025 | Boston, MA

Check In & Light Breakfast 8.00

Workshop A 9.00

Developing Robust, Reproducible & Sensitive Analytical & Functional Assays to Accurately Measure Editing Efficiency, Off-Target Activity & Impact of Editing on Disease

Understanding the level of achieved editing efficiency and the functional effect of editing is vital to measure efficacy and understand the true impact of RNA editing therapies. Reliable, reproducible analytical assays are essential in this process, and can indicate off-target editing, leading to the development of safer, more efficacious RNA editing medicines.

This workshop will cover:

- Developing robust, reproducible analytical assays which mimic human biological mechanisms to accurately measure levels of editing efficiency
- Utilising functional assays to understand the effect of editing on protein function and disease to elucidate efficacy
- Analysing the transcriptome and genome to understand off-target effects and inform biomarker identification and future therapeutic development

Workshop Leaders



Anna Dudkina
Independent RNA Editing Expert

Alan Herbert
Founder
InsideOutBio

Lunch & Networking 12.00

Workshop B 1.00

Navigating RNA Editing Regulatory Challenges & Optimizing Translation of RNA Editing Candidates to Accelerate IND Approval, Streamline Entry into the Clinic & Achieve Commercial Success for RNA Editors

Developing clinically successful therapies with strong efficacy and tolerability relies on robust preclinical development and regulatory compliance in order to maximize patient safety and ultimately drive market success. Navigating the regulatory landscape for RNA editing can be challenging, with unforeseen hurdles to overcome on the path to commercialization.

This workshop will address:

- Understanding the attributes necessary for clinical translation of RNA editing candidates
- Navigating the regulatory path and upholding standards during preclinical and clinical development
- Identifying key hurdles on the path to commercialization and strategizing solutions to accelerate success in the clinic and on the market

Workshop Leaders

TJ Cradick
Chief Technology Officer
HuidaGene Therapeutics

Robert Deans
Chief Technology Officer
Rett Sydrome Research Trust

End of Pre-Conference Workshop Day 4.00

Conference Day One
Wednesday July 30, 2025

8.30 **Check In & Light Breakfast**

Sriram Sathy
Chief Scientific Officer
AIRNA

8.50 **Chair's Opening Remarks**

Optimizing Editing Efficiency by Designing Durable Guide RNA & Effectively Recruiting Editing Machinery to Target Sites to Increase Magnitude of Modification

Maryam Habibian
Director, Head of Medicinal Chemistry
Korro Bio

9.00 **Harnessing Endogenous ADAR for Oligo-Directed RNA Editing**

- The OPERA platform (Oligonucleotide Promoted Editing of RNA), which utilizes synthetic oligonucleotides that recruit ADARs to repair disease-causing mutations at the RNA level
- In addition to repairing standard G-to-A mutations, our platform enables the modulation of protein function by changing the amino acid code
- Updates on the OPERA platform and progress towards the clinic

Sriram Sathy
Chief Scientific Officer
AIRNA

9.30 **Advancing ADAR Mediated RNA Editing Therapies: An Optimal Platform for Treatment of Rare & Common Genetic Diseases**

- **Platform Innovation:** RESTORE+ platform leverages proprietary GalNAc delivery and enhanced chemistry to maximize RNA editing potency, durability, and safety
- **Targeted Liver Delivery:** Engineered for precise ADAR-mediated editing with minimized safety risks, ensuring effective hepatic targeting
- **Lead Program in AATD:** Focused on addressing the genetic root of Alpha-1 Antitrypsin Deficiency to offer a transformative therapeutic option

10.00 **Morning Break & Speed Networking**
This is your opportunity to connect and establish meaningful industry relationships with some of the biggest names in RNA editing!

Unleashing the Full Therapeutic Impact of RNA Editing Through Deep Understanding of RNA Structure & ADAR to Ensure Efficacious Editing

Yang Gao
Assistant Professor
Rice University

11.00 **Molecular Basis of ADAR1-Mediated RNA Editing**

- Outlining the biochemical profiling of ADAR1's RNA substrate preference
- Comprehending atomic resolution structures of ADAR1
- Understanding the domain requirement for RNA editing

Peter Beal
Professor
UC Davis

11.30 **Structure-Guided Optimization of ADAR-Guiding Oligonucleotides**

- High resolution structures of ADAR-RNA complexes solved by X-ray crystallography and cryo-EM
- Describing the impact of specific nucleoside analogs at different positions in ADAR guide strands
- Shedding light on the mechanism of the ADAR deamination reaction and informing the design of highly efficient and selective ADAR guide strand for therapeutic editing using chemically modified RNA

12.00 **Lunch Break & Networking**

Conference Day One
Wednesday July 30, 2025

Exploring Novel Editing Technologies Beyond ADAR to Increase the Scope of RNA Modification & Reach Previously Undruggable Patient Populations

Jacob Borrajo
Founder & Chief Executive Officer
Amber Bio

1.00 Programmable Multi-Kilobase RNA Editing with Splice Editors

- Amber Bio is building Splice Editors, a novel RNA editing technology
- Exploring the ways Splice Editors can achieve multi-kilobase edits with a single AAV
- Understanding how Splice Editors open the aperture for addressable targets

Artem Nemudryi
Assistant Professor
University of Florida

1.30 Break-and-Repair RNA Editing with CRISPR Ribonucleases

- Sequence-specific RNA cleavage by CRISPR ribonucleases and subsequent RNA repair enables programmable RNA editing
- Break-and-repair RNA editing facilitates engineering of RNA viruses without DNA intermediate
- CRISPR-guided RNA breaks are repaired in human cells, which can be used for programmable RNA excisions to restore gene function

TJ Cradick
Chief Technology Officer
HuidaGene Therapeutics

2.00 High Fidelity RNA Editor Development & Studies Supporting the World's First CRISPR/RNA-Targeting Therapy, HG202, for Patients with Neovascular Age-Related Macular Degeneration

- Identification, protein engineering and characterization of high fidelity hfCas12Y
- The opportunity and advantages or RNA editing for Neovascular Age-Related Macular Degeneration (nAMD)
- The molecular composition, mechanism of action, and preclinical animal studies of RNA editor HG202

Omar Abudayyeh
Assistant Professor
Harvard Medical School

Jonathan Gootenberg
Assistant Professor
Harvard Medical School

2.30 Programmable RNA Writing with Trans-Splicing

- Utilizing trans-splicing technology to replace large RNA segments, enabling the correction of multiple mutations at once
- Demonstrated correction for transcripts of therapeutically relevant genes, including those implicated in Huntington's Disease and Rett Syndrome
- Protein-free system design allows for efficient AAV delivery, facilitating in vivo RNA correction strategies

3.00 Afternoon Break & Poster Session

Take this opportunity to showcase your latest RNA editing data with your peers and understand the strategies of your fellow experts. Please visit the website for T&Cs of submitting a poster.

Conference Day One
Wednesday July 30, 2025

Promoting Specific Targeting & Enhanced RNA Delivery to Extra-Hepatic Targets to Maximize Bioavailability & Reach the Therapeutic Potential of RNA Editing

Vincent DiGiacomo
Director, Therapeutic Innovation
Jorna Therapeutics

4.00 **Round Table Discussion: Limiting Off-Target Effects by Ensuring Specific Payload Delivery with Highly-Specific Guide RNA to Prioritize Patient Safety**

- Utilizing transcriptomic data to assess peripheral sequences and empirically monitor off-target edits
- Designing guide RNA for maximum durability and specificity to limit toxicity and immunogenicity
- Determining safety thresholds and acceptable levels of off-target editing

Brian Booth
Director Computational Biology RNAfix
Shape Therapeutics

4.45 **RNAfix Drives Efficient RNA Editing in the Non-Human Primate CNS with IV Delivery**

- RNAfix uses ADAR-recruiting guide RNAs to achieve >90% *in vivo* A-to-I editing efficiency in mouse and NHP CNS with exquisite transcriptome-wide specificity
- Shape's novel AAV capsid SHP-DB1 efficiently crosses the NHP blood-brain-barrier following IV administration, delivering RNA editing across the entire brain without invasive cranial injections
- ShapeTX's integrated platform combines AI-optimized RNAfix guide RNAs, proprietary CNS-tropic AAV capsids, and disruptive stable cell line AAV manufacturing to overcome key gene therapy limitations, enabling scalable, cost-effective solutions to address unmet needs in neurological disorders

Sriram Sathy
Chief Scientific Officer
AIRNA

5.15 **Chair's Closing Remarks & End of Conference Day One**

> "I look forward to interacting with industry leaders in RNA editing to collaboratively address challenges, identify future directions, and celebrate victories."
>
> **Chief Executive Officer, Amber Bio**

> "The field of RNA editing, especially since it is small, benefits from an exchange of ideas and an honest discussion of the challenges. Any insight at several levels – target classes of interest, the regulatory requirements, the major technology limitations that need to be overcome – are incredibly valuable for a small start-up that can very much integrate the knowledge we take in."
>
> **Director, Therapeutic Innovation, Jorna Therapeutics**

Conference Day Two
Thursday July 31, 2025

8.00 **Check In & Light Breakfast**

Venkat Krishnamurthy
Senior Vice President & Head of Platform
Korro Bio

8.50 **Chair's Opening Remarks**

Illuminating the Investment & Partnering Landscape to Guide Future Directions for Research, Growth & Collaboration to Power the Future of RNA Editing

9.00 **Investment Panel: Attracting Investment & Securing Preclinical Funding for Early-Stage RNA Editing Therapeutic Candidates**

- How is RNA editing viewed by investors and what are the directions for growth?
- How to successfully gain funding for preclinical candidates by demonstrating the right data
- What are the hurdles and pitfalls to starting an RNA Editing therapeutics company and what are the timelines, collaborations and levels of investment required

Roger Song
Senior Equity Research Analyst
Jefferies

Steve Seedhouse
Biotechnology Equity Research
Cantor Fitzgerald

Keay Nakae
Director of Research
Chardan

Peter Nell
Chief Executive Officer
Stealth Biotech

10.00 **CEOs' Fireside Chat: Lessons from RNA Editing's CEOs on Driving Clinical & Commercial Development to Accelerate RNA Editors to Patients**

- Delving into the work of RNA editing's leading CEOs to understand their perspectives on the field, ongoing journey to success, and directions for future development
- Learnings to apply to your own RNA editing pipeline and business strategy to accelerate translation and achieve commercial viability

Steve Seedhouse
Biotechnology Equity Research
Cantor Fitzgerald

Ram Aiyar
Chief Executive Officer
Korro Bio

Paul Bolno
Chief Executive Officer
Wave Life Sciences

Kris Elverum
Chief Executive Officer
AIRNA

11.00 **Morning Break & Networking**

Advancing RNA Editing Therapeutic Development with Technological Advances & Strategic Collaborations to Evolve the Scope of Editing to Common Disease

Tehmina Masud
Vice President & Head of Systems & Target Biology
Deep Genomics

12.00 **Uncovering Novel Therapeutic Targets for RNA Editing through Human Genetics & AI**

- Leveraging human genetic data and AI to identify and prioritize genetic targets for RNA editing
- Investigating the target landscape in common diseases with significant unmet therapeutic needs
- Identifying opportunities beyond correcting disease-causing mutations

12.30 **Round Table Discussion: Employing Machine Learning & Computational Biology to Validate Novel Therapeutic Targets, Design Robust Guide RNA & Predict Functional Effect of Editing, Driving the Development of Safe, Selective Editors**

- Utilizing machine learning and computational biology to predict functional effect of editing to assist preclinical development and safeguard patient safety
- Designing high-quality, durable and ultra-specific guide RNA using machine learning tools to improve editing magnitude and safety
- Employing computational tools to apply RNA editing to common disease by targeting multiple mutations and identifying novel therapeutic targets

Tehmina Masud
Vice President & Head of Systems & Target Biology
Deep Genomics

Jeff Wintersinger
Senior Computational Biologist
Deep Genomics

Omar Abudayyeh
Assistant Professor
Harvard Medical School

Jonathan Gootenberg
Assistant Professor
Harvard Medical School

Conference Day Two
Thursday July 31, 2025

1.30 **Lunch Break & Networking**

Expanding the Scope of RNA Editing by Analyzing Human Genetics Data & Identifying Differentiated Novel Targets to Successfully Treat a Wider Range of Indications

2.30 **Panel Discussion: Uncovering Differentiated Targets, Exploring Editing in a Wider Range of Diseases & Identifying Patients Who Could Benefit from RNA Editing**

- Identifying differentiated target sequences using human genomics data and AI
- Exploring editing ceilings and limitations of various targets
- Elucidating treatable diseases and identifying patients with the suitable genotype who could benefit from treatment

Jacob Borrajo
Founder & Chief Executive Officer
Amber Bio

Andrew Fraley
Chief Innovation Officer
Radar Therapeutics

Vincent DiGiacomo
Director, Therapeutic Innovation
Jorna Therapeutics

Chad Weldy
Instructor, Cardiovascular Medicine
Stanford University

3.15 **Defining ADAR1 RNA Editing as a Causal Mechanism of Coronary Artery Disease**

- ADAR1 RNA editing is a critical regulatory mechanism of innate immune activation through preventing endogenous double strand RNA sensing
- Human genetics implicates dsRNA sensing and the inadequate ADAR1 RNA editing as a causal mechanism of coronary artery disease
- Through comprehensive studies utilizing human genetics, primary *in vitro* culture, mouse models of disease, and single cell RNA sequencing, we have defined the mechanism by which ADAR1 RNA editing and dsRNA sensing by MDA5 mediates atherosclerotic disease risk

Gerard Platenburg
Chief Scientific Officer
ProQR Therapeutics

3.45 **Pioneering RNA Modification Beyond Rare Diseases by Exploring Novel Editing Technologies & Targeting Multiple Mutations to Remove the Barriers to Treating Common Diseases**

- Rethinking editing machinery to edit beyond point mutations and specifically modify multiple target sites simultaneously
- Preclinical data to demonstrate the potential of RNA editing outside of rare disease
- Strategically investigating common disease targets to attract investment and pharma partnerships

Venkat Krishnamurthy
Senior Vice President & Head of Platform
Korro Bio

4.15 **Chair's Closing Remarks & End of 6th RNA Editing Summit**

Our 2025 Partners

Industry Partner

Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeted modalities includes RNA editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for sustainably delivering candidates that optimally address disease biology.

www.wavelifesciences.com

Exhibition Partner

Headquartered in Morrisville, NC, USA, Synoligo Biotechnologies is a Contract Research and Development Organization (CRDO) specialized in manufacturing complex and highly modified oligonucleotide for academic, biotech start-up and large pharmaceutical communities. Synoligo is a leading oligonucleotide manufacturing company providing high quality, cost-effective custom oligonucleotides at varying scales for research, diagnostic, and therapeutic applications

www.synoligo.com

Exhibition Partner

Established in 1981, ChemGenes has consistently provided the highest quality Phosphoramidites and Solid Supports in the market. Our Massachusetts facility is setup for therapeutic grade phosphoramidites for GMP grade oligonucleotide manufacturing. Furthermore, ChemGenes carries the widest variety of modified phosphoramidites and solid supports currently used in various areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support

www.chemgenes.com

Get Involved

Katie Orchard
Business Development Manager
+1 617 455 4188
sponsor@hansonwade.com

Partner With Us

RNA Editing Summit
July, 29-31, 2025 | Boston, MA

Are You Committed to Supporting the Development Of Efficient RNA Editors With Targeted Delivery?

The **6th RNA Editing Summit** is your unique opportunity to position yourself amongst the most innovative players in RNA therapeutics to showcase your solutions and capabilities.

Biopharma is increasingly looking to RNA editing as the next revolutionary modality to alter the outcome of disease, yet challenges in **RNA delivery**, **preclinical development** and **manufacturing** are hindering development.

From advanced **analytical testing** to **oligonucleotide sequencing** and **synthesis**, the pioneers gathering at this summit are looking for solutions to drive the specificity, safety and scalability of their RNA editing candidates – can you help?

Partnership Benefits Include:

Position Yourself as The Leading RNA Solution Provider

Connect with a targeted audience of RNA decision-makers looking for support to progress the development of this emerging modality

Keep Your Finger on The Pulse in RNA Editing

Gain first-hand insight directly from RNA leaders to better understand the challenges of developing targeted RNA editors so you can efficiently deliver solutions

Build Important Industry Connections With RNA Leaders

Enjoy 8+ hours of dedicated networking time to unite with the biggest names in RNA editing, pioneering start-ups and academic innovators during the poster session and speed-networking breaks

Maximize Your Brand Visibility & Credibility

Take advantage of branding opportunities and share your newest data on designing robust guide RNA or delivering to extra-hepatic targets, creating a lasting impression of your capabilities

Seniority of Attendees*



C-level/VP/Director - 68%

Manager/Scientist/ Professor - 32%

Types of Companies Attending*



Drug Developer

Academic & Research Institute

Equipment & Service Provider

Other

*Statistics taken from 5th RNA Editing Summit

Get Involved

Katie Orchard
Business Development Manager
+1 617 455 4188
sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.rnaediting-summit.com/take-part/register

+1 617 455 4188

info@hansonwade.com

Enhance RNA editing efficiency and reduce off-target modifications with robust guide RNA and optimized extra-hepatic delivery

Expand and differentiate targets for editing with machine learning to treat previously undruggable indications, including common and rare diseases

Explore the investment and partnership landscape to attract funding and collaborations to drive RNA editing therapies to clinical success

Drug Developer Pricing*	Standard Price	On the Door Price
Conference + 2 Workshops	$4,097 **(save $100)**	$4,197
Conference + 1 Workshop	$3,498 **(save $100)**	$3,598
Conference Only	$2,899 **(save $100)**	$2,999

Academic Pricing**	Standard Price	On the Door Price
Conference + 2 Workshops	$3,497 **(save $100)**	$3,597
Conference + 1 Workshop	$2,998 **(save $100)**	$3,098
Conference Only	$2,499 **(save $100)**	$2,599

Solution & Service Provider Pricing	Standard Price	On the Door Price
Conference + 2 Workshops	$4,997 **(save $100)**	$5,097
Conference + 1 Workshop	$4,298 **(save $100)**	$4,398
Conference Only	$3,599 **(save $100)**	$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline and not offer pay-for services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for the academic & research rate you must be a full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com

Venue

Wyndham Boston Beacon Hill
5 Blossom Street, Boston, MA 02114
www.wyndhambeaconhill.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom